Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.61 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.57 |
| ▸ | SCN4A | P35499 | 4/20 | 0.55 |
| ▸ | KIF11 | P52732 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17279817 | 0.82 | POLB (0.77) | PDPK1NOTUMPOLBPTPN11SCN4A | |
| SCHEMBL14896097 | 0.82 | NOTUM (0.58) | PDPK1NOTUMPOLBPTPN11SCN4A | |
| SCHEMBL10311042 | 0.80 | POLB (0.57) | PDPK1NOTUMPOLBPTPN11SCN4A | |
| SCHEMBL104517 | 0.77 | SCN4A (0.79) | PDPK1NOTUMPOLBPTPN11SCN4A | |
| SCHEMBL3392174 | 0.76 | PDPK1 (1.00) | PDPK1NOTUMPOLBPTPN11SCN4A | |
| SCHEMBL28205218 | 0.76 | SCN4A (0.61) | PDPK1NOTUMPOLBPTPN11SCN4A | |
| SCHEMBL1725632 | 0.76 | KIF11 (0.47) | NOTUMKIF11CCNB2CDK1CCNB1 | |
| SCHEMBL25795132 | 0.75 | NOTUM (0.50) | PDPK1NOTUMPOLBPTPN11SCN4A | |
| SCHEMBL15230775 | 0.75 | METAP2 (0.69) | NOTUMCYP1A2 | |
| SCHEMBL9977867 | 0.74 | LTA4H (0.49) | LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100528876-C | Pyrrazolo-pyrimidine derivatives | HOFFMANN LA ROCHE (CH) | 2009-08-19 | — | — | CN | claimed |
| CN-1964973-A | Pyrrazolo-pyrimidine derivatives | HOFFMANN LA ROCHE (CH) | 2007-05-16 | — | — | CN | claimed |
| US-11767297-B2 | Compounds for inhibiting TNIK and medical uses thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2023-09-26 | — | — | US | disclosed |
| CN-114411178-B | Polysubstituted pyrazole compound and electrochemical synthesis method thereof | 南京工业大学 | 2023-06-30 | — | — | CN | disclosed |
| US-20230039679-A1 | COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2023-02-09 | — | — | US | disclosed |
| EP-3177611-B1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION AS (DK) | 2021-10-06 | — | — | EP | disclosed |
| EP-3177611-B1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION AS (DK) | 2021-10-06 | — | — | EP | disclosed |
| US-10689383-B2 | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | NUEVOLUTION A/S (DK) | 2020-06-23 | — | — | US | disclosed |
| US-10689383-B2 | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | NUEVOLUTION A/S (DK) | 2020-06-23 | — | — | US | disclosed |
| US-20170327503-A1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION A/S (DK) | 2017-11-16 | — | — | US | disclosed |
| US-20170327503-A1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION A/S (DK) | 2017-11-16 | — | — | US | disclosed |
| CN-101273040-B | Diazolylpyrazolopyrimidines as MGLUR2 antagonists | HOFFMANN LA ROCHE | 2011-11-09 | — | — | CN | disclosed |
| CN-100528876-C | Pyrrazolo-pyrimidine derivatives | HOFFMANN LA ROCHE (CH) | 2009-08-19 | — | — | CN | disclosed |
| CN-101273040-A | Oxadiazolyl pyrazolopyrimidines as MGLUR2 antagonists | HOFFMANN LA ROCHE (CH) | 2008-09-24 | — | — | CN | disclosed |
| CN-1964973-A | Pyrrazolo-pyrimidine derivatives | HOFFMANN LA ROCHE (CH) | 2007-05-16 | — | — | CN | disclosed |
| EP-1761541-A1 | PYRRAZOLO-PYRIMIDINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-14 | — | — | EP | disclosed |
| WO-2005123738-A1 | PYRRAZOLO-PYRIMIDINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689383-B2 | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | RORA, RORC, RORB | PDPK1 1700/4885NOTUM 3326/4885POLB 1528/4885 |
| US-11767297-B2 | Compounds for inhibiting TNIK and medical uses thereof | TNNI3K, TNK1, TNIK | PDPK1 340/4885NOTUM 2557/4885POLB 4408/4885 |
| US-20170327503-A1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | PPARD, PPARG, RORC | PDPK1 1268/4885NOTUM 2693/4885POLB 560/4885 |
| US-20230039679-A1 | COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF | TNNI3K, TNK1, TNIK | PDPK1 340/4885NOTUM 2557/4885POLB 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.